Prothena Reports Fourth Quarter and Full Year 2023 Financial

Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0...

Related Keywords

United States , Canada , American , Billy Dunn , Bristol Myers Squibb , Development Collaboration , European Medicines Agency , Drug Administration , Movement Disorders , Global Neuroscience Research , Nasdaq , Exchange Commission , Novo Nordisk , Office Of Neuroscience , Prothena Corporation , International Congress , Walgreens , Company On Twitter Prothenacorp , American Society Of Hematology , Gene Kinney , Chief Executive Officer , Fast Track , Bristol Myers , Myers Squibb , Mayo Stage , Orphan Drug Designation , European Medicines , American Society , Special Protocol Assessment , Full Year , Quarterly Report , Annual Report , Ended December , Markets ,